Atea Pharmaceuticals, Inc.
NASDAQ:AVIRBiotechnology
-$0.04 today
- Market cap
- $320.41M
- Beta
- 0.32
- P/E (TTM)
- -2.0
- EPS (TTM)
- -$2.14
Volume 0.34M
Average 0.34M
Balance Sheet
Inspect the capital base behind the business.
Assets
$315.22M
FY 2025 · Annual
-32.2% YoYLiabilities
$39.78M
FY 2025 · Annual
+54.2% YoYEquity
$275.43M
FY 2025 · Annual
-37.2% YoYBalance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 764.38M | 646.71M | 143.82M | 64.7M | 95.71M |
| Short-term Investments | 0 | 0 | 434.28M | 390.03M | 206.12M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | (0) | 14.21M | 12.35M | 7.63M | 9.16M |
| Total Current Assets | 772.4M | 660.92M | 590.46M | 462.36M | 310.99M |
| Property, Plant & Equipment (Net) | 184K | 4.09M | 3.12M | 2.12M | 1.09M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 305K | 198K | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 0 | 1.49M | 1.4M | 197K | 3.14M |
| Total Non-current Assets | 489K | 5.79M | 4.51M | 2.31M | 4.23M |
| Total Assets | 772.89M | 666.71M | 594.97M | 464.67M | 315.22M |
| Account Payables | 4.53M | 2.55M | 4.25M | 4.46M | 12.95M |
| Short-term Debt | 0 | 0 | 0 | 0 | 843K |
| Tax Payables | 0 | 99K | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 27.57M | 8.65M | 0 | 7.44M | 19.56M |
| Total Current Liabilities | 56.88M | 18.48M | 32.38M | 18.6M | 39.78M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 5.93M | 5.26M | 5.76M | 6.36M | 0 |
| Total Non-current Liabilities | 5.93M | 7.66M | 7.4M | 7.2M | 0 |
| Total Liabilities | 62.82M | 26.14M | 39.78M | 25.8M | 39.78M |
| Common Stock | 83K | 83K | 83K | 84K | 78K |
| Retained Earnings | 56.03M | (59.88M) | (195.84M) | (364.22M) | (522.57M) |
| Accumulated OCI | (0) | (684K) | 207K | 233K | 174K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 710.08M | 640.57M | 555.19M | 438.87M | 275.43M |
| Total Debt | 197K | 3.12M | 2.4M | 1.64M | 843K |
| Net Debt | (764.18M) | (643.59M) | (141.42M) | (63.05M) | (94.87M) |
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $79.3M |
| Short-term Investments | $176.7M |
| Other Current | $7.2M |
| Total Current Assets | $263.2M |
| PP&E (Net) | $831.0K |
| Other Non-current | $3.0M |
| Total Non-current Assets | $3.9M |
| Total Assets | $267.1M |
Analysis
Selected assets total $267.1M for Latest. The largest visible component is Short-term Investments at $176.7M, about 66.2% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G/A | SC 13G/A filing | Nov 13, 2026 | |
| 10-Q | Quarterly report | Nov 9, 2026 | |
| 8-K | Current report | Nov 9, 2026 | |
| 8-K | Current report | Nov 9, 2026 | |
| SC 13G | SC 13G filing | Oct 6, 2026 |
How much cash does AVIR have?
Atea Pharmaceuticals, Inc. (AVIR) reported $95.71M in cash and equivalents in fiscal 2025.
How much debt does AVIR carry?
Atea Pharmaceuticals, Inc. (AVIR) reported $843,000.00 of total debt, with net debt of -$94.87M.
Continue the stock analysis
Jump to another research area for this company.